Marksans Pharma Ltd

MARKSANS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,335 cr, stock is ranked 705
High RiskStock is 3.33x as volatile as Nifty
56.350.70 (-1.23%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,335 cr, stock is ranked 705
High RiskStock is 3.33x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
9.79
PB RatioPB Ratio
2.58
Dividend YieldDiv. Yield
0.44%
Sector PESector PE
36.71
Sector PBSector PB
4.89
Sector Div YldSctr Div Yld
0.70%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Investor PresentationView older 

Nov 10, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20182019202020210.921.001.131.380.030.080.120.24
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Updates 
Announced OnJan 11, 2022

Marksans Pharma Limited has informed the Exchange regarding 'Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2021 received from Bigshare Services Private Limited, Registrar and Transfer Agent of the Company.'. | Download

Marksans Pharma Limited has informed the Exchange regarding 'Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2021 received from Bigshare Services Private Limited, Registrar and Transfer Agent of the Company.'. | Download

Press Release 
Announced OnJan 11, 2022

Marksans Pharma Limited has informed the Exchange regarding a press release dated January 11, 2022, titled "Marksans Pharma Limited announces final approval for Cetirizine Hydrochloride Tablets 5 mg and 10mg from US FDA.". | Download

Marksans Pharma Limited has informed the Exchange regarding a press release dated January 11, 2022, titled "Marksans Pharma Limited announces final approval for Cetirizine Hydrochloride Tablets 5 mg and 10mg from US FDA.". | Download

Cash Dividend 
Ex. DateSep 15, 2021

Final • Div/Share: ₹ 0.25

See all events